QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 immunitybio-presents-long-term-overall-survival-data-in-non-small-cell-lung-cancer-patients-and-announces-registrational-intent-phase-3-trials-with-anktiva-and-checkpoint-immunotherapy-at-world-conference-on-lung-cancer

Phase 2 data presented at the World Conference on Lung Cancer showing a prolonged median overall survival of over 14 months in ...

 piper-sandler-maintains-neutral-on-immunitybio-lowers-price-target-to-475

Piper Sandler analyst Joseph Catanzaro maintains ImmunityBio (NASDAQ:IBRX) with a Neutral and lowers the price target from $...

 immunitybios-anktiva-now-available-to-patients-through-both-commercial-and-government-insurance-programs-also-announced-plans-to-expand-its-bladder-cancer-program-globally-notably-in-the-european-union-and-india

  ANKTIVA® reaches U.S. commercial and Medicare insurance coverage milestone within three months of FDA approval

 immunitybio-announces-study-of-anktiva-in-combination-with-the-adher2dc-cancer-vaccine-as-a-potential-therapy-to-control-endometrial-cancer

The QUILT 502 trial is testing ImmunityBio's N-803 (ANKTIVA®) in combination with the AdHER2DC investigational vaccine for ...

 chinas-bilibili-and-ollies-bargain-outlet-were-among-10-mid-cap-stocks-with-biggest-gains-in-the-last-week-june-16-june-22-2024-are-they-in-your-portfolio

Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11...

 why-immunitybio-stock-is-trading-higher-thursday

The company announced insurance coverage of ANKTIVA, a immunotherapy used to treat non-muscle invasive bladder cancer that was...

 immunitybio-announces-insurance-coverage-of-anktiva-across-multiple-states-with-first-commercial-doses-administered

Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immu...

 immunitybio-completes-gmp-drug-substance-manufacturing-sufficient-for-170000-doses-of-anktiva

ANKTIVA® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA pro...

 serum-institute-of-india-inks-large-scale-supply-deal-for-bcg-use-in-immunitybios-bladder-cancer-combo-therapy

Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expa...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION